Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Omega Diagnostics ( (GB:CNSL) ) has issued an update.
Cambridge Nutritional Sciences plc has reported a 12% increase in total income for the year ending March 31, 2025, reaching approximately £11.1 million, bolstered by a successful settlement with the DHSC. The company achieved a gross profit margin of around 65%, and an adjusted EBITDA of £0.4 million, indicating strong financial performance and effective cost management. The company is optimistic about the upcoming financial year, with a positive start attributed to a growing revenue pipeline and strategic investments in production and sales. The resolution of a historical legal issue is expected to allow CNS to focus on enhancing business performance, with expectations of further growth in revenue and profitability in 2026 and beyond.
More about Omega Diagnostics
Cambridge Nutritional Sciences plc (CNS) is a specialist medical diagnostics company that focuses on health and nutrition products. The company emphasizes a personalized and functional approach to health, catering to markets in the UK, Europe, the USA, and India, where it is developing strong distributor relationships.
Average Trading Volume: 167,643
Technical Sentiment Signal: Sell
Current Market Cap: £6.78M
For detailed information about CNSL stock, go to TipRanks’ Stock Analysis page.